Per 
Item #: SCP-XXXX
Object Class: Safe
Special Containment Procedures: SCP-XXXX is to be stored in a Class 1 Anomalous Object container at Site-29 when not undergoing testing or use by foundation personnel. Access to the object must be approved by at least two researchers of Level 3 clearance or higher. Subjects utilizing SCP-XXXX are required to undergo psychiatric evaluation prior and post exposure to SCP-XXXX (See Addendum XXXX-B). Testing of SCP-XXXX must be monitored by Site-29 medical staff in the event of psychological and behavioral abnormalities in subjects post exposure to SCP-XXXX. Under no circumstances are personnel that have been administered amnestetics to be allowed access to SCP-XXXX (See Addendum XXXX-A).
Description: SCP-XXXX is a black eye mask composed of silk, polyester, and rubber. The object exhibits no unusual physical properties apart from its tensile strength, which resembles that of hardened steel. The mask itself is consistent with the Manta brand of sleep masks produced between the years of 2005 and 2012. However, the mask itself lacks the company’s manufacturer markings.
When worn, the wearer is transported to a corridor stretching beyond the subject's range of vision, with doors lining its walls. Various tests indicate that the amount of doorways and the physical length of the corridor change depending on the subject. GPS tracking of subjects has proven ineffective, implying that the corridor may exist in a separate reality.
Subjects report tranquility and increased curiosity inside the corridor, pushing them to navigate it. After three minutes, the subject will attempt to open one of the doors and proceed within. Subjects report to observe a third person perspective scene of an event from their past within, with a majority of these scenes prompting a positive response from subjects1.
Subjects have also observed vocalizations (hereby designated SCP-XXXX-1) post conclusion of the observed scene. In all cases, SCP-XXXX-1 will attempt conversation with the subject in regards to the scene. In all cases, SCP-XXXX-1 prompts an overall positive outlook from the subject, and is often described as a voice similar to that of a close friend or family member related to the subject.
When SCP-XXXX is removed, subjects return to their location prior to interaction with SCP-XXXX with no observable deterioration in physical or mental health regardless of time elapsed. It is of note that individuals suffering from PTSD2 or other stress related conditions observe the most significant change in overall demeanor post exposure to SCP-XXXX. Testing into the potential use as an antidepressant or therapeutic device is ongoing.
Discovery: SCP-XXXX was discovered by foundation field agents on 5/7/20██ following numerous reports of a new mental health treatment program developed by DreamScape Pharmaceuticals™, based in Tampa, Florida3. Foundation agents confirmed the anomalous nature of SCP-XXXX after field agents arranged appointments with the clinic in question, and a demonstration of the procedure was observed. Class-B amnestetics were supplied to all staff at the clinic and all documented individuals that underwent treatment via SCP-XXXX were subsequently questioned, amnesticized, and released. SCP-XXXX was later transported to its current containment at site-29.
Addendum XXXX-A: Given the potential breach of secrecy SCP-XXXX presents for individuals that undergo amnestic treatment, such subject experimentation is unanimously prohibited by the O5 Council. (see Experiment II for details).
Addendum XXXX-B: Following Experiment III, all experimentation with SCP-XXXX must be approved by the two researchers of Level 3 clearance or higher. All subjects are to undergo psychiatric evaluation prior to and following the use of SCP-XXXX to avoid any potential hazardous behavioral development within site staff (see Experiment III for details).
